Comparing an Automatic PWV Analyser to Pulse Pressure in Hemodialysis
NCT ID: NCT02327962
Last Updated: 2014-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
143 participants
OBSERVATIONAL
2011-01-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A cohort of 143 patients from 4 dialysis units has been followed measuring MogPWV and PP every 3 to 6 months and compared to a control group of non-CKD patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The increase in PWV related to the above-mentioned risk factors also accelerates with age \[7\].
Both PWV and PP correlate to mortality in the dialysis population \[15-17\]: for each PWV increase of 1 m/s Blacher et al. found an all-cause mortality-adjusted OR of 1.39 (95% CI, 1.19 to 1.62) \[16\] while for each 10 mmHg increase in PP, Tozawa et al. found an increase in all-cause mortality relative risk of 8% \[17\].
Risk factors such as age, hypertension, previous history of heart diseases and diabetes influence the evolution of Pulse Wave Velocity before dialysis initiation whereas their impact during the course of dialysis has not yet been demonstrated \[18\]. In this regard, a study published in 2013 by Utescu et al. indicated that the only risk factor significantly associated with PWV progression was the level of an advanced glycation end-product known as pentosidine \[18\]. The results of this study confirmed that specific uraemia-related risk factors can be identified and possibly quantified.
In the above-mentioned study, the rate of PWV progression (+0.84 m/s per year) was surprisingly high, especially when projected over time as a function of the average life span of ESRD patients on dialysis. Another critical data point outlined in the study was the discrepancy in the annual rate of change in carotid-femoral compared to carotid-radial Pulse Wave Velocity, which was +0.84 m/s per year and -0.66 m/s per year, respectively. The authors of the study postulate that this discrepancy may be due to anatomical differences between central (elastic) and peripheral (muscular) arteries and that the latter could deploy an adaptive response to central aortic stiffening. Although interesting, these data raise some concerns about the promising possibility of using the brachial artery as a site for PWV estimation, even if based on a non-operator dependent method.
Furthermore, another limitation identified in the literature currently available on prospective longitudinal studies analysing the PWV behaviour on dialysis patients, is the lack of a control group made up of patients with similar characteristics and co-morbidities but without kidney failure \[2,16,18\].
In the light of this, we decided to test a Mobil-O-Graph, a simple device estimating PWV (MogPWV) through a modified sphygmomanometer on the brachial artery and to analyse the baseline and follow-up MogPWV values in a cohort of dialysis patients and in a control group with the same risk factors but without kidney failure.
The aim of the study was answering the following 4 questions, which also reflect both the primary and the secondary endpoints of the trial: 1. Does PWV estimated by Mobil-O-Graph on the brachial artery, be more sensitive for vascular aging and better discriminate the dialysis population from the control group than pulse pressure? (primary endpoint); 2. Is MogPWV progression faster during dialysis than in the pre-dialysis setting? (secondary endpoint); 3. Are there specific risk factors that correlate to MogPWV progression? (secondary endpoint); 4. Does mortality correlate to MogPWV? (secondary endpoint).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hemodialysis
Hemodynamic measurements with PWV
No interventions assigned to this group
Control
Hemodynamic measurements with PWV
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ability to understand the information presented and to sign the informed consent
* chronic hemodialysis for at least 8 weeks.
Exclusion Criteria
* inability to understand the information presented and to sign the informed consent
* acute disease requiring hospitalization at the time of patient enrolment
* evidence of stenosis of the subclavian artery of the arm without shunt or of the non-shunt arm chosen to be used for the Mobil-O-Graph measurements
* atrial fibrillation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ospedale Regionale di Locarno
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luca Gabutti, MD
Head of Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luca Gabutti, MD
Role: PRINCIPAL_INVESTIGATOR
Ente Ospedaliero Cantonale, Bellinzona
References
Explore related publications, articles, or registry entries linked to this study.
Salvade I, Schatti-Stahlin S, Violetti E, Schonholzer C, Cereghetti C, Zwahlen H, Berwert L, Burnier M, Gabutti L. A prospective observational study comparing a non-operator dependent automatic PWV analyser to pulse pressure, in assessing arterial stiffness in hemodialysis. BMC Nephrol. 2015 Apr 23;16:62. doi: 10.1186/s12882-015-0058-9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LG2014
Identifier Type: -
Identifier Source: org_study_id